China Companion Animal Health Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

China Companion Animal Health Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

The China Companion Animal Health market was valued at USD 633.71 million in 2021 and is expected to reach USD 1241.52 million in 2027 with a CAGR of 11.71% during the forecast period (2022-2027).

Supply disruption and medicine shortages of veterinary medicines had been observed in China, primarily due to the temporary lockdowns of manufacturing sites, export bans, and increased demand for medicine to treat COVID-19. A slight short-term negative impact is witnessed on companion animal healthcare, primarily due to the reduced veterinary visits, along with the shortage of veterinary medicines, during the outbreak of COVID-19. An article published in the journal of Animals in July 2021 titled “Animal Transmission of SARS-CoV-2 and the Welfare of Animals during the COVID-19 Pandemic” indicated that during the lockdown imposed on the COVID-19 pandemic, people were forced to leave their pets behind, which significantly affected the growth of the market. Also, some organizations in China announced campaigns to kill any cats or dogs found outdoors, to prevent disease transmission. Such activities affecting the lives of the pet animals drastically affected the growth of the companion animal health market in the nation during the COVID-19 pandemic.

The China companion health market is primarily driven by the rising popularity of pet ownership and growing spending on animal healthcare, and rising awareness regarding the various treatments available for companion animal diseases.

In recent years, there has been a significant increase in the adoption of dogs and cats that have been observed in China, as they are the most favorite companions of human beings. According to an article titled “Pets in Hong Kong and China: A Booming Market” published in April 2022 by AHK Hong Kong, in 2020, the total number of pets in Hong Kong, including smaller mammals such as rabbits and rodents, as well as birds, fish, and reptiles, was over 1.2 million. With the increasing animal population in the country, the demand for vaccination is expected to rise to maintain the companion animals' proper health. The pet industry in China is booming, and the growth rates in the region are comparable to other developed countries. Hence, the increase in pet adoption has helped in driving the companion health market.​

With the increase in the number of companion animals, owners are becoming increasingly aware of their pet’s health and nutrition and are also seeking veterinary services. This, in turn, is creating a growing demand for diversified forms of companion animal healthcare products.

Furthermore, there are also increasing initiatives by the government and animal welfare associations for creating awareness about the various disease against companion animals, which will augment the growth of the market as awareness can prevent various animal-related diseases. For instance, according to an article titled “Vital Surveillances: Epidemiology of Animal Rabies — China, 2010–2020” published in China Center for Disease Control and Prevention (CCDC) Weekly in September 2021, around 212 animal rabies cases and 1,132 suspected rabies deaths were reported during the period of 2010 to 2020. This significant rise in disease prevalence has triggered companies to produce advanced vaccines and pharmaceuticals.

​In addition, The growing investments by key market players to develop advanced solutions for pet care is also one of the key contributors to the growth of the china companion animal health market.​ For instance, in September 2020, Boehringer Ingelheim acquired an equity stake in China-based New Ruipeng Group. Pet owners and the larger animal health industry in China can make use of a wide range of services provided by the quickly expanding NRP Group, including veterinarian treatment and e-commerce.

The availability of a considerable number of counterfeit animal products and drugs in the market, including a number of fake or copied companion animal drugs, are identified as an obstruction to the growth of the market for genuine animal drug products. These drugs are found to be unsafe and ineffective, as well as harmful to the health and well-being of pets, and may affect a large section of the pets population. ​This is likely to hamper the market growth over the forecast period.

Key Market TrendsVaccines Contributed the Largest Share in Terms of Revenues in the Therapeutics Segment

Vaccines are a crucial part of preventive healthcare for companion animals. They are categorized as core vaccines and non-core vaccines. Core vaccines are compulsory for all companion animals, whereas non-core vaccines are indicated by companion animal lifestyle or based on geographical area. In China, new advanced vaccines are manufactured containing genetically engineered components derived from those disease agents.

In dogs, Rabies, Distemper, Hepatitis/Adenovirus, Parvovirus, and Parainfluenza are the core vaccines while, Bordetella, Leptospirosis, Lyme Disease, Giardia, and Canine Influenza H3N8 are the non-core vaccines. In cats, FVRCP (distemper)is the vaccine to protect against Rhinotracheitis (feline herpes), Calicivirus, and Panleukopenia. Also, Rabies FeLV (feline leukemia) vaccines are given to cats.

According to the Chinese government, all dogs and cats must be vaccinated against rabies annually. Moreover, in recent years, there has also been an increased awareness about animal vaccinations and the overall health of dogs and cats in China. As per the article titled “Progress in the Development of Animal Rabies Vaccines in China” published in the journal of China CDC Weekly in September 2021, during the period of past three years, China had issued about twenty-five million doses of domestic inactivated rabies vaccine and twelve million doses of imported inactivated rabies vaccine each year, with a total of about thirty-seven million doses.

Moreover, the vaccines segment of the Chinese veterinary healthcare market is expected to be driven by innovations in vaccines, growing awareness of animal health, increasing investments by government bodies and associations, and increased expenditure on the healthcare of companion animals. In September 2021, in remote Chinese villages, ACTAsia, a WSAVA Educational Partner, conducted rabies immunization clinics.

However, the COVID-19 impact in the country from 2019 to 2020 had affected the services provided to companion animals as supplies reduced significantly for some period, and the pet owners were confined to their homes for a significant period. Such factors dropped the treatment rates across the country. However, in the forecast period, the services provided are likely to have a positive impact on the market.

Competitive Landscape

The China Companion Animal Health Market is a consolidated market with few dominant players. Key market players in the market include China Animal Husbandry Co. Ltd, Shenyang Dachang Medical Imaging Technology Co., Ltd., Elanco Animal Health, Merck & Co., Vetoquinol SA, Virbac, and Zoetis Inc., among others.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

Please note: This publisher does offer titles that are created upon receipt of order. If you are purchasing a PDF Email Delivery option above, the report will take approximately 2 business days to prepare and deliver.